LSV Associates Reports Dilution of Ownership in ALX Oncology Holdings Inc. below 5% Threshold

LSV Associates, LLC and its affiliates filed an Amendment No. 3 to their Schedule 13D for ALX Oncology Holdings Inc. (ALXO) on May 27, 2026. The filing reports that the Reporting Persons have ceased to be the beneficial owners of more than 5% of the Issuer's common stock. This reduction in ownership percentage to approximately 1.2% (representing 1,549,132 shares for LSV Associates, LLC) occurred on or about February 2, 2026. Notably, the decrease was not due to the sale or disposition of shares by the reporting entities, but rather resulted from dilution following the Issuer's issuance of additional common stock. The reporting group includes various Lightstone Ventures entities and individual managing directors Michael A. Carusi, Jean George, and Henry A. Plain Jr., who share voting and dispositive power. The ownership percentage is calculated based on 134,562,917 shares outstanding as of May 1, 2026. No transactions in the Issuer's securities were conducted by the Reporting Persons in the sixty days preceding the filing.